[{"orgOrder":0,"company":"Monash University","sponsor":"Monash Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"L-Carnosine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monash University \/ Monash Health","highestDevelopmentStatusID":"8","companyTruncated":"Monash University \/ Monash Health"}]

Find Clinical Drug Pipeline Developments & Deals for 2-(3-Aminopropanoylamino)-3-(3H-Imidazol-4-Yl)Propanoic Acid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Monash University

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Monash University

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Carnosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peripheral Arterial Disease.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          February 18, 2019

                          Lead Product(s) : L-Carnosine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Monash Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank